Disease Activity Monitoring in Patients With Giant Cell Arteritis Study

Inclusion Criteria: 1. Clinical GCA diagnosis established/confirmed by a rheumatologist and positive GCA imaging or biopsy at diagnosis \< 3 years. 2. Clinical remission at the time of inclusion, defined as * Having adhered for ≥ 8 weeks prior to inclusion to either (a) the planned tapering of glucocorticoid therapy, or (b) the planned glucocorticoid-sparing DMARD treatment (with or without glucocorticoids). * Absence of, or no worsening of, symptoms attributed to GCA in ≥ 8 weeks. * Normal CRP level (\< 10 mg/L) within 7 days before inclusion. 3. Current prednisolone dosage of ≥ 5 mg if glucocorticoid monotherapy. 4. A continuous tapering of monotherapy or combination therapy is planned. 5. Age \> 50 years. 6. Study participants must be able to speak and understand spoken and written Danish. Exclusion Criteria: 1. Intra-articular, intravenous or intramuscular glucocorticoid ≤ 7 weeks prior to inclusion. 2. Study participants who are unable to complete online questionnaires cannot participate in the GCA-PRO component of the study. 3. Presence of cognitive impairment, including clinically significant dementia, that may interfere with the ability to provide informed consent or comply with study procedures.